Search

Royalty Pharma PLC (Class A)

Abierto

SectorSanidad

58.1 -0.27

Resumen

Variación precio

24h

Actual

Mínimo

57.65

Máximo

58.48

Métricas clave

By Trading Economics

Ingresos

-589M

-295M

Ventas

44M

674M

P/B

Media del Sector

31.419

55.725

BPA

1.32

Rentabilidad por dividendo

1.56

Margen de beneficios

-43.713

Empleados

100

EBITDA

-387M

176M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+12.74% upside

Dividendos

By Acuity

Rentabilidad por dividendo

Media del Sector

1.56%

2.25%

Próximas Ganancias

4 nov 2026

Fecha Próximo Dividendo

9 dic 2026

Próxima Fecha de Ex Dividendo

13 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

848M

34B

Apertura anterior

58.37

Cierre anterior

58.1

Noticias sobre sentimiento de mercado

By Acuity

15%

85%

11 / 339 Clasificación en Healthcare

Royalty Pharma PLC (Class A) Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 sept 2026, 19:25 UTC

Royalty Pharma PLC shares are rising, reflecting notable market strength, although they remain below the 20-day moving average and near the one-month range's lower end.

23 sept 2026, 19:51 UTC

Royalty Pharma PLC shares fell sharply, reaching a session low just before 1 PM, as the broader market declines and remains below its 20-day moving average.

22 sept 2026, 20:06 UTC

Correlated Moves

Royalty Pharma PLC is trading higher, likely influenced by Amgen Inc.'s positive Phase 3 OASIZ 301 study results, despite earlier pulling back from a session high.

21 sept 2026, 20:06 UTC

Royalty Pharma PLC's shares are trading roughly flat, remaining below the 20-day moving average and near the lower end of their one-month range.

18 sept 2026, 20:06 UTC

Royalty Pharma PLC shares fell sharply on Friday, closing significantly below its 20-day moving average and near the lower end of its one-month range.

17 sept 2026, 23:06 UTC

Royalty Pharma PLC declined in after-market trading, moving lower since Thursday's close and positioning it below its 20-day moving average.

16 sept 2026, 23:06 UTC

Royalty Pharma PLC is trading lower in after-market hours, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

15 sept 2026, 23:16 UTC

News

Royalty Pharma announced a $7.5 million donation to Blood Cancer United. Shares are lower in after-market trading amid rising Treasury yields.

14 sept 2026, 20:07 UTC

Royalty Pharma PLC shares are higher today, reflecting a modest gain since Friday. Broader market concerns over rising crude oil prices may be influencing sentiment.

11 sept 2026, 20:08 UTC

Royalty Pharma PLC shares are lower today, pulling back from earlier gains amid broader market dynamics and inflation pressures influencing Federal Reserve policy.

10 sept 2026, 23:46 UTC

Royalty Pharma PLC shares are higher in after-market trading, continuing a rise since Thursday's close, though still below the 20-day moving average.

9 sept 2026, 20:07 UTC

News

Royalty Pharma shares lower today, following a decline after Novartis' trial failure. Analysts suggest the drop may be overdone amid stable royalty expectations.

8 sept 2026, 21:01 UTC

Royalty Pharma PLC shares are higher in after-market hours, reflecting broader market dynamics despite no specific company news identified.

5 sept 2026, 00:01 UTC

News

Royalty Pharma PLC shares fell in after-market hours following the failed Phase 3 trial of pelacarsen, impacting its funding agreement with Ionis.

4 sept 2026, 22:14 UTC

Royalty Pharma PLC shares are trading lower during after-market hours, breaking a trend of higher daily closes. No specific news was identified for the decline.

3 sept 2026, 23:05 UTC

Royalty Pharma PLC shares are lower in after-market hours, with no specific news identified for the decline. The stock remains above its 20-day moving average.

2 sept 2026, 23:06 UTC

Royalty Pharma PLC shares are lower in after-market hours, reflecting a slight decline since Wednesday's close, despite earlier recovery attempts.

1 sept 2026, 20:09 UTC

Royalty Pharma PLC is rising as strength in the pharmaceuticals sub-sector boosts shares. The stock remains near its one-month high despite a recent pullback.

31 ago 2026, 23:16 UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting positive market sentiment. The stock remains near the upper end of its one-month trading range.

28 ago 2026, 20:07 UTC

Royalty Pharma PLC shares are lower today amid broader market declines and rising U.S. Treasury yields, reflecting ongoing volatility in the pharmaceuticals sector.

27 ago 2026, 23:11 UTC

Royalty Pharma PLC shares are higher in after-market trading, supported by a favorable performance backdrop and positioning above the 20-day moving average.

26 ago 2026, 23:16 UTC

Royalty Pharma PLC shares are higher in after-market trading, currently above their 20-day moving average and near the upper end of their one-month range.

25 ago 2026, 20:07 UTC

Royalty Pharma PLC shares are higher today, continuing an upward trend since Monday. Lower Treasury yields are supporting investor sentiment in the market.

24 ago 2026, 20:06 UTC

Royalty Pharma PLC shares are near unchanged as market sentiment is influenced by rising oil prices and geopolitical tensions from new U.S. sanctions against Iran.

21 ago 2026, 19:26 UTC

Royalty Pharma PLC shares are higher, reflecting a broader rebound in U.S. stocks amid economic uncertainties and rising inflation. The asset remains above its 20-day moving average.

20 ago 2026, 23:11 UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a decline from earlier in the session amid mixed broader market sentiment.

19 ago 2026, 20:02 UTC

Royalty Pharma PLC shares are higher today, driven by strong investor interest in pharmaceuticals and unusually high market volume during regular trading hours.

18 ago 2026, 23:21 UTC

Royalty Pharma PLC shares are higher in after-market trading, continuing an upward trend from previous sessions. No specific news was identified for this movement.

17 ago 2026, 19:36 UTC

Royalty Pharma PLC shares are trading higher during Monday's session, recovering from an earlier dip and remaining above the 20-day moving average.

15 ago 2026, 00:01 UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a routine decline since Friday's close amid mixed global equity market performance.

Comparación entre iguales

Cambio de precio

Royalty Pharma PLC (Class A) previsión

Precio Objetivo

By TipRanks

12.74% repunte

Estimación a 12 Meses

Media 65.714 USD  12.74%

Máximo 70 USD

Mínimo 62 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Royalty Pharma PLC (Class A) Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

7

Comprar

0

Mantener

0

Vender

Sentimiento

By Acuity

11 / 339 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.